<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434642</url>
  </required_header>
  <id_info>
    <org_study_id>AVF4095g</org_study_id>
    <nct_id>NCT00434642</nct_id>
  </id_info>
  <brief_title>A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma</brief_title>
  <acronym>OCEANS</acronym>
  <official_title>A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the
      safety and efficacy of bevacizumab, administered in combination with carboplatin with
      gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary
      peritoneal, or fallopian tube carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
    <description>PFS was defined as the time from randomization to disease progression (PD), as determined by the investigator, or death due to any cause. PD: At least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started; the appearance of 1 or more new lesions; and/or the unequivocal progression of existing non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With an Objective Response as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
    <description>An objective response was the occurrence of either a partial response (PR) or complete response (CR). PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. CR: The disappearance of all target and non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (OR) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
    <description>Duration of OR was analyzed in the subset of patients who achieved an OR. The duration of OR was defined as the time from the initial CR or PR until documented PD or death. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization through July 19, 2013 (up to 6 years, 3 months)</time_frame>
    <description>Overall survival was defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Had a Gastrointestinal Perforation (GIP)</measure>
    <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
    <description>A gastrointestinal perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Had at Least 1 Adverse Event</measure>
    <time_frame>From randomization through July 19, 2013 (up to 6 years, 3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin and gemcitabine + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin and gemcitabine + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin was provided as commercially available drug.</description>
    <arm_group_label>Carboplatin and gemcitabine + bevacizumab</arm_group_label>
    <arm_group_label>Carboplatin and gemcitabine + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine was provided as commercially available drug.</description>
    <arm_group_label>Carboplatin and gemcitabine + bevacizumab</arm_group_label>
    <arm_group_label>Carboplatin and gemcitabine + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.</description>
    <arm_group_label>Carboplatin and gemcitabine + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.</description>
    <arm_group_label>Carboplatin and gemcitabine + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age â‰¥ 18 years

          -  Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred

          -  No prior chemotherapy in the recurrent setting

          -  Measurable disease

          -  Recovered from prior radiation therapy or surgery

        Exclusion Criteria:

          -  Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian
             tube carcinoma

          -  History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal
             abscess

          -  Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who
             require parenteral hydration, parenteral nutrition, or tube feeding

          -  Patients with evidence of abdominal free air not explained by paracentesis or recent
             surgical procedure

          -  Current, recent, or planned participation in an experimental drug study

          -  History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor
             (VEGF) or VEGF receptor-targeted agent use

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure (CHF)

          -  History of myocardial infarction or unstable angina

          -  History of stroke or transient ischemic attack (TIA)

          -  Known central nervous system (CNS) disease except for treated brain metastasis

          -  Significant vascular disease or recent peripheral arterial thrombosis

          -  History of hemoptysis

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amreen Husain, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2007</study_first_posted>
  <results_first_submitted>September 26, 2011</results_first_submitted>
  <results_first_submitted_qc>September 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2011</results_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avastin</keyword>
  <keyword>Ovarian carcinoma</keyword>
  <keyword>Peritoneal carcinoma</keyword>
  <keyword>Peritoneal cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Fallopian tube carcinoma</keyword>
  <keyword>OCEANS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin and Gemcitabine + Placebo</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
        </group>
        <group group_id="P2">
          <title>Carboplatin and Gemcitabine + Bevacizumab</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patientâ€™s weight at baseline and remained the same throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Blinded Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression Per RECIST</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision To Terminate Study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's Decision-Discontinue Treatment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12">One participant did not continue into the open-label treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression Per RECIST</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin and Gemcitabine + Placebo</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
        </group>
        <group group_id="B2">
          <title>Carboplatin and Gemcitabine + Bevacizumab</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patientâ€™s weight at baseline and remained the same throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="242"/>
            <count group_id="B3" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="10.2"/>
                    <measurement group_id="B2" value="60.5" spread="9.8"/>
                    <measurement group_id="B3" value="61.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
        <description>PFS was defined as the time from randomization to disease progression (PD), as determined by the investigator, or death due to any cause. PD: At least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started; the appearance of 1 or more new lesions; and/or the unequivocal progression of existing non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
        <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
        <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
          <description>PFS was defined as the time from randomization to disease progression (PD), as determined by the investigator, or death due to any cause. PD: At least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started; the appearance of 1 or more new lesions; and/or the unequivocal progression of existing non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
          <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="11.40" upper_limit="12.71"/>
                    <measurement group_id="O2" value="8.4" lower_limit="8.31" upper_limit="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between the 2 treatment groups, ie, that the hazard ratio is equal to 1. The alternative hypothesis was that progression free survival was longer in the carboplatin and gemcitabine + bevacizumab group, ie, that the hazard ratio is not equal to 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A P-value &lt; 0.05 was required for significance.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The analysis was stratified for time since the last platinum therapy (6-12, &gt; 12 months) and cytoreductive surgery for recurrent disease (yes, no).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.484</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.388</ci_lower_limit>
            <ci_upper_limit>0.605</ci_upper_limit>
            <estimate_desc>The hazard ratio was estimated using Cox regression. The hazard ratio is relative to the carboplatin and gemcitabine + placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With an Objective Response as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
        <description>An objective response was the occurrence of either a partial response (PR) or complete response (CR). PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. CR: The disappearance of all target and non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
        <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
        <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With an Objective Response as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
          <description>An objective response was the occurrence of either a partial response (PR) or complete response (CR). PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. CR: The disappearance of all target and non-target lesions. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
          <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5"/>
                    <measurement group_id="O2" value="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference in the percentage of patients with an objective response between the 2 treatment groups. The alternative hypothesis was that a larger percentage of patients had an objective response in the carboplatin and gemcitabine + bevacizumab group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A P-value &lt; 0.05 was required for significance.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The analysis was stratified for time since the last platinum therapy (6-12, &gt; 12 months) and cytoreductive surgery for recurrent disease (yes, no).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.0</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
            <estimate_desc>The difference in response rates and the 95% confidence intervals for response rates were computed using the normal approximation to the binomial distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response (OR) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
        <description>Duration of OR was analyzed in the subset of patients who achieved an OR. The duration of OR was defined as the time from the initial CR or PR until documented PD or death. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
        <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
        <population>Subset of the intent-to-treat population: All patients randomized to treatment who achieved an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response (OR) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)</title>
          <description>Duration of OR was analyzed in the subset of patients who achieved an OR. The duration of OR was defined as the time from the initial CR or PR until documented PD or death. Lesions were assessed by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound every 9 weeks.</description>
          <population>Subset of the intent-to-treat population: All patients randomized to treatment who achieved an objective response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.36" upper_limit="11.83"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.31" upper_limit="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from randomization to death from any cause.</description>
        <time_frame>From randomization through July 19, 2013 (up to 6 years, 3 months)</time_frame>
        <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from randomization to death from any cause.</description>
          <population>Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="30.32" upper_limit="35.84"/>
                    <measurement group_id="O2" value="32.9" lower_limit="29.80" upper_limit="37.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6479</p_value>
            <p_value_desc>Summaries of duration of overall survival (median, percentiles) were estimated from Kaplan-Meier curves. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The analysis was stratified for time since the last platinum therapy (â‰¤12, &gt;12 months) and cytoreductive surgery for recurrent disease (Yes, No).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.952</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.771</ci_lower_limit>
            <ci_upper_limit>1.176</ci_upper_limit>
            <estimate_desc>The hazard ratio was estimated using Cox regression. The hazard ratio is relative to the carboplatin and gemcitabine + placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Had a Gastrointestinal Perforation (GIP)</title>
        <description>A gastrointestinal perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
        <time_frame>From randomization through September 17, 2010 (up to 3 years, 5 months)</time_frame>
        <population>Safety population: All patients who received at least 1 dose of protocol treatment. Due to errors in drug administration, the safety population included 247 patients in the carboplatin and gemcitabine + bevacizumab group and 233 patients in the carboplatin and gemcitabine + placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had a Gastrointestinal Perforation (GIP)</title>
          <description>A gastrointestinal perforation is a hole that develops through the entire wall of the stomach, small intestine, large bowel, or gallbladder.</description>
          <population>Safety population: All patients who received at least 1 dose of protocol treatment. Due to errors in drug administration, the safety population included 247 patients in the carboplatin and gemcitabine + bevacizumab group and 233 patients in the carboplatin and gemcitabine + placebo group.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Had at Least 1 Adverse Event</title>
        <time_frame>From randomization through July 19, 2013 (up to 6 years, 3 months)</time_frame>
        <population>Safety population: All patients who received at least 1 dose of protocol treatment. Due to errors in drug administration, the safety population included 247 patients in the carboplatin and gemcitabine + bevacizumab group and 233 patients in the carboplatin and gemcitabine + placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin and Gemcitabine + Bevacizumab</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Carboplatin and Gemcitabine + Placebo</title>
            <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had at Least 1 Adverse Event</title>
          <population>Safety population: All patients who received at least 1 dose of protocol treatment. Due to errors in drug administration, the safety population included 247 patients in the carboplatin and gemcitabine + bevacizumab group and 233 patients in the carboplatin and gemcitabine + placebo group.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization through July 19, 2013</time_frame>
      <desc>Safety population: All patients who received at least 1 dose of protocol treatment. Due to errors in drug administration, the safety population included 247 patients in the carboplatin and gemcitabine + bevacizumab group and 233 patients in the carboplatin and gemcitabine + placebo group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin and Gemcitabine + Bevacizumab</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patientâ€™s weight at baseline and remained the same throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Carboplatin and Gemcitabine + Placebo</title>
          <description>Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemolytic Uraemic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ileus Spastic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombosis In Device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Septic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Soft Tissue Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Tumour Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Reversible Posterior Leukoencephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ureteral Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Embolism Venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="247"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

